Hoth Therapeutics, Inc. (HOTH) — SEC Filings

Latest SEC filings for Hoth Therapeutics, Inc. (HOTH), explained in plain English.

Sentiment Overview: 4 bearish, 29 neutral, 1 mixed

Recent Filings (34)

• Hoth Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · 2026-04-02T16:18:12-04:00 [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed an 8-K on April 2, 2026, reporting on a material definitive agreement and unregistered sales of equity securities. The filing incl
• Hoth Therapeutics Files Prospectus Supplement for Stock Offering — 424B5 · 2026-04-02T13:39:13-04:00 [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed a prospectus supplement (424B5) on April 2, 2026, detailing the terms of a securities offering. The filing indicates the company i
• Hoth Therapeutics' Losses Widen Amid Soaring R&D Costs — 10-Q · 2025-11-12T00:00:00.000Z [bearish] Risk: high
  Hoth Therapeutics, Inc. reported a net loss of $4,105,801 for the three months ended September 30, 2025, significantly wider than the $2,229,017 loss for the sa
• Hoth Therapeutics Files 8-K — 8-K · 2025-10-17T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on October 17, 2025, reporting other events and financial statements. The filing does not contain specific financial figure
• Hoth Therapeutics Files 8-K: Other Events Reported — 8-K · 2025-09-12T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed an 8-K on September 12, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these eve
• Hoth Therapeutics Files 8-K on Officer/Director Changes — 8-K · 2025-08-22T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of cert
• Hoth Therapeutics Files 10-Q, Remains Pre-Revenue Biotech — 10-Q · 2025-08-12T00:00:00.000Z [bearish] Risk: high
  Hoth Therapeutics, Inc. (HOTH) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-revenue biotechnology status. The company contin
• Hoth Therapeutics Files 8-K on Security Holder Vote Matters — 8-K · 2025-08-05T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on August 5, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain sp
• 8-K Filing — 8-K · 2025-06-24T00:00:00.000Z [neutral]
• Hoth Therapeutics Files 8-K — 8-K · 2025-06-20T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting other events and financial statements as of June 18, 2025. The filing does not contain specific
• Hoth Therapeutics Seeks 183% Boost in Equity Incentive Plan Shares — DEF 14A · 2025-06-16T00:00:00.000Z [mixed] Risk: medium
  Hoth Therapeutics, Inc. (HOTH) has filed a DEF 14A for its 2025 Annual Meeting of Shareholders, scheduled for August 5, 2025, at 12:00 p.m. Eastern Time, to be
• Hoth Therapeutics Files 8-K — 8-K · 2025-06-09T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting on other events and financial statements. The filing does not contain specific details about new
• Hoth Therapeutics Faces Delisting Concerns — 8-K · 2025-05-16T00:00:00.000Z [bearish] Risk: high
  Hoth Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing indicates potent
• Hoth Therapeutics Files Q1 2025 10-Q — 10-Q · 2025-05-12T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Nevada, is in the pharmaceutic
• Hoth Therapeutics Files 8-K: Other Events — 8-K · 2025-05-02T00:00:00.000Z [neutral] Risk: medium
  On May 2, 2025, Hoth Therapeutics, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details about the nature of these eve
• Hoth Therapeutics Announces Board Changes and Officer Compensation — 8-K · 2025-04-15T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. announced on April 9, 2025, a change in its board of directors. Specifically, Dr. Robert L. Smith has been appointed as a new director,
• Hoth Therapeutics Files 2024 Annual Report — 10-K · 2025-03-28T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed its 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Nevada with its principal executive offices in
• Hoth Therapeutics Files 8-K: Material Agreement & Financial Restatement — 8-K · 2025-03-25T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed an 8-K on March 25, 2025, reporting a material definitive agreement and a non-reliance on previously issued financial statements.
• Hoth Therapeutics Files 8-K — 8-K · 2025-02-07T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on February 7, 2025, reporting other events and financial statements/exhibits. The filing does not contain specific financi
• Hoth Therapeutics Files 8-K — 8-K · 2025-01-24T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on January 24, 2025, reporting on events that occurred on January 23, 2025. The filing primarily concerns other events and
• Hoth Therapeutics Amends Q3 2024 Financial Filing — 8-K · 2024-12-02T00:00:00.000Z [neutral] Risk: low
  On December 2, 2024, Hoth Therapeutics, Inc. filed an 8-K report detailing an amendment to its previously filed Form 10-Q for the quarterly period ended Septemb
• Hoth Therapeutics Files 8-K — 8-K · 2024-11-20T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on November 20, 2024, reporting other events and financial statements. The filing details the company's corporate structure
• Hoth Therapeutics Files Q3 2024 10-Q Report — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2024. The company, incorporated in Nevada, is involved in th
• Hoth Therapeutics Files 8-K — 8-K · 2024-11-08T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on November 8, 2024, to report the entry into a material definitive agreement and to file financial statements and exhibits
• Hoth Therapeutics Faces Delisting Concerns — 8-K · 2024-11-01T00:00:00.000Z [bearish] Risk: high
  Hoth Therapeutics, Inc. filed an 8-K on November 1, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing
• Hoth Therapeutics Files Q2 2024 10-Q Report — 10-Q · 2024-08-09T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Nevada, is involved in the phar
• Hoth Therapeutics Files 8-K on Security Holder Votes — 8-K · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on August 7, 2024, to report on matters submitted to a vote of security holders. The filing does not contain specific detai
• Hoth Therapeutics Files 2024 Proxy Statement — DEF 14A · 2024-06-18T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed its Definitive Proxy Statement (DEF 14A) on June 18, 2024, for its annual meeting of shareholders scheduled for August 7, 2024. Th
• Hoth Therapeutics Relocates Executive Offices — 8-K · 2024-06-17T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting a change in its principal executive offices to 590 Madison Avenue, 21st Floor, New York, NY 100
• Hoth Therapeutics Files Q1 2024 10-Q Report — 10-Q · 2024-05-14T00:00:00.000Z [neutral] Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2024. The company, incorporated in Nevada, is involved in the ph
• Hoth Therapeutics Files S-1 for Potential Stock Offering — S-1 · 2024-04-11T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed an S-1 registration statement on April 11, 2024, indicating plans to offer securities. The company, incorporated in Nevada with it
• Hoth Therapeutics Files 2023 Annual Report — 10-K · 2024-03-28T00:00:00.000Z [neutral] Risk: medium
  Hoth Therapeutics, Inc. filed its annual report for the fiscal year ended December 31, 2023. The company, incorporated in Nevada, operates in the Pharmaceutical
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Hoth Therapeutics Files 8-K: Administrative Update, Nasdaq Listing Confirmed — 8-K · 2024-01-09T00:00:00.000Z [neutral]
  Hoth Therapeutics, Inc. filed an 8-K on January 9, 2024, reporting an 'Other Event' that occurred on January 8, 2024. This filing primarily serves to update adm